Blunt-point for friable tissues like the liver
Although most current studies are confounded by metabolic comorbidities, recent findings by Nicolau et al 5 begin to address this gap by evaluating the effects of GLP-1 RAs in metabolically healthy patients, providing preliminary support for a direct immunologic mechanism
With the advent of CGM, which allows for measuring interstitial glucose levels every 5 min, real-time visualization of glycemic trajectories has become possible
Average Weight Loss Percentage by GLP-1 Medication vs Placebo Average Weight Loss Percentage by GLP-1 Medication vs Placebo Sustained Weight Loss and Long-term Outcomes Long-term efficacy data from the STEP 5 trial demonstrates the sustainability of weight loss with GLP-1 therapy ^3
But breakfast is a critical nutritional touchpoint
4.2 Tirzepatide in weight regulation and metabolic improvement Obesity is one of the major risk factors for OSAS, and weight reduction has been associated with improvements in OSAS-related symptoms
